AU654699B2 - Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive - Google Patents

Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive Download PDF

Info

Publication number
AU654699B2
AU654699B2 AU12487/92A AU1248792A AU654699B2 AU 654699 B2 AU654699 B2 AU 654699B2 AU 12487/92 A AU12487/92 A AU 12487/92A AU 1248792 A AU1248792 A AU 1248792A AU 654699 B2 AU654699 B2 AU 654699B2
Authority
AU
Australia
Prior art keywords
core
vaccine
protein
additive
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU12487/92A
Other languages
English (en)
Other versions
AU1248792A (en
Inventor
Bernard Meignier
Catherine Moste-Deshairs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9409015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU654699(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Publication of AU1248792A publication Critical patent/AU1248792A/en
Application granted granted Critical
Publication of AU654699B2 publication Critical patent/AU654699B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU12487/92A 1991-01-24 1992-01-24 Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive Expired AU654699B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9100806 1991-01-24
FR9100806A FR2671974A1 (fr) 1991-01-24 1991-01-24 Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
PCT/FR1992/000066 WO1992013002A1 (fr) 1991-01-24 1992-01-24 Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal

Publications (2)

Publication Number Publication Date
AU1248792A AU1248792A (en) 1992-08-27
AU654699B2 true AU654699B2 (en) 1994-11-17

Family

ID=9409015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12487/92A Expired AU654699B2 (en) 1991-01-24 1992-01-24 Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive

Country Status (10)

Country Link
EP (1) EP0522138B2 (enrdf_load_stackoverflow)
AT (1) ATE234861T1 (enrdf_load_stackoverflow)
AU (1) AU654699B2 (enrdf_load_stackoverflow)
CA (1) CA2078985C (enrdf_load_stackoverflow)
DE (1) DE69232962T3 (enrdf_load_stackoverflow)
FR (1) FR2671974A1 (enrdf_load_stackoverflow)
IL (1) IL100765A (enrdf_load_stackoverflow)
NZ (1) NZ241398A (enrdf_load_stackoverflow)
WO (1) WO1992013002A1 (enrdf_load_stackoverflow)
ZA (1) ZA92510B (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1998046262A1 (en) * 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041880A1 (fr) * 1980-06-05 1981-12-16 Synthelabo Procédé pour isoler des antigènes glycoprotéiques viraux et son application à la préparation de vaccins
WO1986004242A1 (en) * 1985-01-28 1986-07-31 Medical Research Council Improvements relating to influenza vaccine
WO1990014361A1 (en) * 1989-05-24 1990-11-29 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041880A1 (fr) * 1980-06-05 1981-12-16 Synthelabo Procédé pour isoler des antigènes glycoprotéiques viraux et son application à la préparation de vaccins
WO1986004242A1 (en) * 1985-01-28 1986-07-31 Medical Research Council Improvements relating to influenza vaccine
WO1990014361A1 (en) * 1989-05-24 1990-11-29 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Also Published As

Publication number Publication date
DE69232962T2 (de) 2005-06-23
ZA92510B (en) 1992-11-25
EP0522138B1 (fr) 2003-03-19
IL100765A (en) 1996-06-18
DE69232962T3 (de) 2007-11-08
CA2078985C (fr) 2004-11-09
FR2671974A1 (fr) 1992-07-31
AU1248792A (en) 1992-08-27
NZ241398A (en) 1994-08-26
WO1992013002A1 (fr) 1992-08-06
CA2078985A1 (fr) 1992-07-25
EP0522138A1 (fr) 1993-01-13
IL100765A0 (en) 1992-09-06
FR2671974B1 (enrdf_load_stackoverflow) 1995-03-03
DE69232962D1 (de) 2003-04-24
ATE234861T1 (de) 2003-04-15
EP0522138B2 (fr) 2007-02-14

Similar Documents

Publication Publication Date Title
Tamura et al. Cross‐protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules
Eliasson et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine
JP4240237B2 (ja) ワクチン組成物
US6743900B2 (en) Proteosome influenza vaccine
US6485729B1 (en) Neuraminidase-supplemented compositions
US7192595B2 (en) Peptide-based vaccine for influenza
US4009258A (en) Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
US4029763A (en) Influenza vaccine containing purified neuraminidase antigen and method of using the same
Ben Ahmeida et al. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus
van der Plas et al. Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (Gem) particles (Flugem): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly
US5741493A (en) Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
Potter et al. A new surface-antigen-adsorbed influenza virus vaccine II. Studies in a volunteer group
AU654699B2 (en) Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive
Virelizier et al. The role of humoral immunity in host defence against influenza A infection in mice
US20100196495A1 (en) Delivery of flu antibodies to surfaces in contact with air
CN109180784B (zh) 一种促进禽流感和/或新城疫疫苗的免疫反应的法氏囊活性六肽及应用
US6921543B2 (en) Immunomodulatory preparation
Webster et al. Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)—a new equine influenza virus
Morein et al. Immunity against parainfluenza-3 virus in cattle: anti-neuraminidase activity in serum and nasal secretion
Honda-Okubo et al. Immunogenicity in mice and non-human primates of an Advax-CpG55. 2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine
Potter et al. Immune response of mice to immunization with subunit influenza A vaccine in DTP vaccine
Vinson et al. Delivery of a thermo-enzymatically treated influenza vaccine using pulmonary surfactant in pigs
CN102526722A (zh) 人用狂犬疫苗
WO1997041891A1 (en) Compositions and methods for protection against immunologically diverse isolates of influenza virus